Market Signal Briefing

After taking a quick look at the Polymarket odds for Bitcoin (BTC +7.27%), you'll probably be tempted to look elsewhere for upside in 2026. A clear majority of Polymarket traders think that Bitcoin will be rangebound between $55,000 and $75,000 for the rest of the year.

But that doesn't mean you can't still make money on Bitcoin this year. Here are a few ideas for turning a profit in a down year for Bitcoin.

Bet against Bitcoin What's the old saying? "If you can't beat 'em, join 'em." The same goes for Bitcoin. If you absolutely think Bitcoin is done for the year, then why not start predicting that Bitcoin will decline in price over the course of 2026?

Image source: Getty Images.

On Polymarket, traders are giving Bitcoin a 78% chance of hitting $55,000 this year, a 63% chance of hitting $50,000 this year, and a 51% chance of hitting $45,000 this year. You could easily buy event contracts at any one of those price points, and then cash in as soon as Bitcoin falls in price from its current level of $68,000.

You can also predict that Bitcoin will go (almost) all the way to zero. Polymarket traders are giving Bitcoin a 4% chance of hitting rock bottom at a price of just $5,000. Just be forewarned: Those are roughly the same odds (5%) that Polymarket traders give Bitcoin to hit a price of $250,000 this year. Which one do you really think is more likely?

Bitcoin-related stocks Another strategy for making money in a down crypto market is looking for different plays within the Bitcoin blockchain ecosystem. You can still get exposure to Bitcoin, but in a more indirect manner, by investing in Bitcoin-related stocks.

For example, you could invest in Bitcoin mining stocks. The hottest players right now are Bitcoin miners that are transitioning some of their compute power to AI. These stocks give investors exposure to both Bitcoin and artificial intelligence.

Today's Change

(

10.27

%) $

13.62

Current Price

$

146.30

Or, you could invest in Bitcoin treasury companies. For a long stretch of time, Strategy (MSTR +10.27%) was able to outperform Bitcoin. However, starting in mid-2025, that trade started to fizzle. Strategy is down 10% for the year and 45% over the past 12 months.

Bitcoin derivatives Finally, there's one super-risky strategy that could pay off big: Trading Bitcoin financial derivatives. For example, hedge fund managers are buying and selling options on the iShares Bitcoin Trust (IBIT +7.08%), which now ranks as the top Bitcoin ETF in the world, in terms of assets under management (AUM).

If you think about it, prediction market event contracts are similar to deep out-of-the-money call options. For example, if you predict that Bitcoin will climb back to the $100,000 price level this year, then you are really buying a long-dated call option with a $100,000 strike price and a December 2026 expiration.

From my perspective, it's a lot easier to figure out the correct pricing for a Bitcoin event contract than a Bitcoin call option. You don't need a sophisticated options-pricing model or any knowledge of "the Greeks." I'm personally in the camp that ultra-cheap Bitcoin prediction market contracts are the way to go if you're determined to speculate on the future price of Bitcoin.

What about a long-term buy and hold strategy? Long-time crypto investors recognize what's happening with Bitcoin right now. It's going through one of its famous four-year cycles of boom and bust.

So just wait around a little bit longer, and the price of Bitcoin should eventually recover. If that's the case, then the ultimate strategy for Bitcoin remains unchanged: Buy Bitcoin at super-cheap prices, and hold on for dear life (HODL).

TL;DR:

U.S. government support for digital assets has driven institutional interest in Layer-1 networks. Solana recorded a 290% increase in tokenized gold volume, reaching 25.5 million tokens. The network’s speed and scalability are decisive factors for the mass adoption of Real-World Assets (RWA). The recent shift in crypto market sentiment, fueled by a pro-blockchain stance from the U.S. executive, has put the spotlight on major network infrastructure. In this scenario, analysts identify Solana as a CLARITY Act winner due to its ability to manage tokenized assets with superior efficiency compared to its competitors.

Solana would be by far the biggest assymetric winner of the clarity bill passing. The total market cap of US equities is over 50T dollars, 20x larger than the entire crypto market cap. SEC chairman Paul Atkins has expressed his desire to move ALL of that on chain. So where is… pic.twitter.com/6wP8bI2Kd7

— Max Resnick (@MaxResnick) March 3, 2026

Investor confidence is not merely speculative; it responds to solid fundamentals of scalability. Therefore, the market anticipates that this regulation will provide the legal clarity needed for banks to use fast networks for the settlement of traditional financial instruments.

The Rise of Digital Gold and Solana’s Infrastructure A key data point reinforcing this thesis is the performance of tokenized gold within the ecosystem. A report from The Kobeissi Letter reveals that this sector recently hit all-time highs, with volumes jumping 290% above previous records due to global geopolitical tensions.

Notably, Solana managed to capture a massive share of this activity, processing gold transactions equivalent to 25.5 million tokens. This milestone highlights the divergence between general market fear and the actual adoption of digital assets backed by physical goods on this network.

In summary, the success of the CLARITY Act could transform 5.6 billion internet users into potential buyers of bonds and other on-chain assets. If Solana maintains its dominance in executing these contracts, it will consolidate its position as the preferred infrastructure for the new digital economy.

With a 6% gain, Bitcoin is trading at the $71.3K mark. The market has seen $201.34M in BTC liquidations. 5% gain has been recorded in the last few hours within the crypto market. It has pushed the majority of the digital assets into bullish territory. The largest and dominant token, Bitcoin (BTC), has followed suit, registering a 6.76% surge in value. After multiple recovery attempts, the asset is finally on the way to reclaiming the recent highs. 

BTC opened the day trading at a low of $66,237, and with a gradual bullish turn, the price moved up to a high of $71,886. Bitcoin is currently trading at $71,362, and the trading volume has reached $62.28 billion. Also, the BTC market has seen a liquidation of $201.34 million. Consequently, the asset’s Fear and Greed Index is at 10, reporting extreme fear.

With the 4-hour trading pattern, Bitcoin faces a bullish encounter. The price may rise to the resistance zone at $71.4K. Further gains on the upside could trigger the mighty bulls to invite the golden cross to unfold. The asset’s price would eventually climb to a high of $71.5K. 

On the flip side, if the asset’s price chart turns red, it could slip to revisit the $71.2K support range. An extended correction on the downside might push the death cross to take place. Gradually, the potential bears would send the Bitcoin price toward the $71.1K or even lower. 

Can Bitcoin’s Bullish Momentum Sustain in the Near Term? BTC’s Moving Average Convergence Divergence line is found above the signal line, which hints at bullish momentum. This would remain valid as long as the MACD stays above, and then may continue trending upward. Moreover, the Chaikin Money Flow indicator of Bitcoin at 0.12 displays moderate buying pressure, with the money flowing in. This shows ongoing accumulation, and if CMF climbs higher, it can reinforce bullish momentum. 

The daily Relative Strength Index (RSI) at 67.41 signals a strong bullish condition. With buyers firmly in control, Bitcoin may approach the overbought zone. Also, there is a chance that the asset is getting closer to a level where short-term consolidation could occur.

Furthermore, the Bull Bear Power (BBP) value of BTC at 4,467.51 reflects extremely strong bullish dominance. The asset’s price is trading significantly above its average level. It currently displays powerful upward momentum and strong demand in the market.

Top Updated Crypto News

11% Rally Ignites MUBARAK: Can Bulls Conquer the Next Major Range?

Content Writer | Crypto Enthusiast | Bridging Literature and Blockchain

Journalist

Posted: March 5, 2026

River [RIVER] staged a decisive move, surging roughly 34%, the largest gain recorded across the crypto market over the past 24 hours. Buyer sentiment tilted sharply in favor of the bulls.

Despite the sharp rally, investors still needed caution regarding the longer-term outlook. Indicators tracking investor sentiment weakened notably.

Only 58% of investors maintained a bullish stance on the altcoin as of press time, down from 82% earlier in the day. The shift suggested that confidence had moderated despite strong price action.

Momentum remains elevated Although some investors have reduced their bullish positioning through sentiment-based metrics, technical indicators show that price momentum remains firmly intact.

At the time of writing, the Moving Average Convergence Divergence (MACD) neared the positive territory, signaling a bullish market structure for RIVER.

The continued expansion of green histogram bars, each forming higher than the previous one, reinforced the view that upward momentum strengthened. This pattern typically reflected sustained buying pressure and supported a constructive outlook.

Source: TradingView

Similarly, the Relative Strength Index (RSI), which measures the speed and magnitude of price changes, placed RIVER in favorable bullish territory.

An RSI reading between 50 and 70 typically signals bullish control. RIVER’s RSI hovered near 55, suggesting buyers still dominated.

At the same time, the altcoin remained below overbought conditions. This left room for additional upside if momentum held.

A critical resistance threat However, a significant resistance level stood directly ahead.

This zone previously triggered a price rejection and remained a critical level. Historically, such resistance often attracts selling pressure after sharp rallies.

If RIVER failed to break above this zone, a pullback could become increasingly likely.

Source: TradingView

Should rejection occur, RIVER could decline toward the $12.24 region. That scenario implied an average correction of roughly 38%.

A milder rejection could produce a shallower pullback with limited downside.

However, aggressive profit-taking could accelerate losses and expose the asset to deeper downside pressure.

Short-term outlook remains constructive In the short term, the Derivatives market data support the possibility of continued upside.

At the time of writing, Open Interest increased by $27.2 million, bringing total Open Interest to $125.16 million. The rise indicated renewed trader participation.

Source: CoinGlass

Meanwhile, Funding Rates turned positive and read 0.0078%. This meant long positions paid shorts, reflecting bullish bias in perpetual futures markets.

The combination of rising Open Interest and positive Funding Rates suggested fresh capital entered the market with a bullish orientation.

If MACD and RSI continued trending upward, and leveraged longs remained concentrated on the upside, RIVER could extend its rebound.

Final Summary RIVER surged 34% in 24 hours, making it the top-performing asset across the crypto market during the period. Investor sentiment weakened despite the rally, with bullish positioning dropping from 82% to 58%.

TLDR:

Solana processed 3.4 billion transactions in February, an 11% increase compared to the previous month. The network outperformed BNB Chain’s activity by eight times and left behind the combined volume of Ethereum’s Layer 2s. The ecosystem concentrates 53% of the USDC stablecoin supply, reaffirming itself as a liquidity hub. In a context of uncertainty last month, Solana’s operational dominance became evident. Data from DeFi Dev Corp. indicates that the network processed over 3.4 billion transactions, contrasting with the slowdown of Bitcoin and Ethereum.

This volume positions Solana above its closest competitor: BNB Chain, which recorded 424 million transactions. For its part, in the Ethereum ecosystem, main activity is shifting towards Layer 2 solutions like Base and Arbitrum, although even these networks combined fall far short of the performance of the network led by Anatoly Yakovenko.

Institutional support and stabilization after capitulation Beyond network metrics, institutional interest was a fundamental support during the recent period of volatility. Spot Solana ETFs captured net inflows worth $950 million, demonstrating persistent confidence despite the SOL price suffering a 12% monthly drop.

On a technical level, Santiment data suggests that the panic selling phase could be coming to an end after recording realized losses close to $1.3 billion early in the month. Currently, selling pressure appears to be diminishing as the asset seeks to stabilize above the $90 zone.

In summary, Solana’s ability to continue with double digits in a bear market underlines its technical efficiency. If this transactional momentum is maintained, the network will consolidate itself as the leading infrastructure for payments and high-frequency decentralized applications in 2026.

Breaking Signal·Market Impact: Medium

Decred jumped 10.03% to $32.61, topping the gainers chart, according to CoinGecko data. Zcash rose 9.09% to $240.25, while Ethereum added 7.71% to $2,125.56. On the downside, NEAR Protocol fell 8.22% to $1.27.

Top Gainers Decred (DCR) rose 10.03% to $32.61, lifting its market cap to $565.41M. Decred runs a hybrid proof-of-work/proof-of-stake design, pairing miner security with ticket-based staking and on-chain governance via Politeia. Its architecture includes a non-custodial DEX for trading without intermediaries. The hybrid model’s ticket staking reduces free-float supply at the margin, a structural feature traders monitor during sharp upswings.

Zcash (ZEC) gained 9.09% to $240.25, valuing the network at $3.98B. ZEC facilitates shielded transfers using zk-SNARKs and is stewarded by Electric Coin Co. alongside the Zcash Foundation. No specific news has been tied to the move. Privacy coins often see outsized swings when liquidity rotates into higher beta names.

Pi Network (PI) advanced 8.00% to $0.1832, pushing its market cap to $1.75B. The project promotes mobile-first “mining” and aims to migrate a large user base onto an open mainnet through a phased rollout with identity checks. The rally extended recent interest in lower-priced tokens with sizable communities.

Dogecoin (DOGE) climbed 7.89% to $0.0968, bringing its market cap to $14.84B. The 2013-era meme token is merge-mined with Litecoin and often trades as a high-beta proxy for risk appetite. Traders pointed to broader altcoin rotation. DOGE remains sensitive to liquidity bursts and social momentum.

Ethereum (ETH) added 7.71% to $2,125.56, taking its market cap to $256.69B. Ethereum anchors the leading smart contract ecosystem, now secured by validators post-Merge, with withdrawals enabled since Shanghai. Scaling advances such as proto-danksharding have shifted activity toward layer-2s, keeping fee dynamics and throughput in focus. Today’s move reinforced strength across large-cap smart contract platforms.

Top Losers NEAR Protocol (NEAR) fell 8.22% to $1.27, with market cap at $1.63B. NEAR is a sharded smart contract network using Nightshade and supports an EVM-compatible environment via Aurora. The token is used for fees and staking, making price sensitive to shifts in risk appetite. Developer-facing features like human-readable accounts and streamlined onboarding remain core to its pitch even as price cooled.

XDC Network (XDC) lost 5.14% to $0.0349, taking its market cap to $696.17M. XDC is an enterprise-focused, EVM-compatible chain linked to tokenized trade finance efforts such as TradeFinex. The downtick kept XDC in the red against a mixed alt tape. Attention stays on real-world asset rails that could expand on-chain settlement for trade workflows.

Morpho (MORPHO) dropped 4.16% to $1.88, putting its market cap at $1.03B. Morpho builds an optimization layer for DeFi lending, matching lenders and borrowers atop protocols like Aave and Compound, and is governed by the MORPHO token. Governance assets tied to emissions, liquidity mining, and parameter changes can exhibit elevated volatility. The slide left MORPHO among the day’s weaker DeFi names by percentage move.

Stable (STABLE) declined 3.99% to $0.0282, valuing it at $580.36M. Public details on the asset remain limited on mainstream trackers, and no project-specific headlines surfaced. The move leaves STABLE fourth on the losers list by percentage change. Traders will watch for any disclosures that clarify token utility and supply dynamics.

MemeCore (M) slipped 3.91% to $1.36, with a market cap of $2.37B. Branding and positioning around meme exposure can make such tokens particularly reactive to flows and sentiment shifts. The decline was the mildest percentage loss among today’s top five decliners. Liquidity pockets around round numbers often shape intraday action in meme-linked names.

Market Outlook Dispersion stayed wide, with the top gainer up 10.03% while the biggest loser shed 8.22%. Large caps participated on the upside as Ethereum rose 7.71% and Dogecoin added 7.89%, while NEAR’s 8.22% drop showed pockets of weakness.

Into the next sessions, watch Bitcoin’s direction for read-through on risk appetite, Ethereum layer-2 fee trends after recent scaling milestones, and any fund flow updates or macro data prints that could sway liquidity. Traders will also track whether today’s privacy and meme moves extend or fade.

SourcesCoinGecko

This article was written with AI assistance and reviewed by the The Currency analytics editorial team. Information presented is sourced from publicly available reports. The Currency analytics strives for accuracy but cannot guarantee completeness. This article does not constitute financial advice.

Post Views: 1

Bitcoin price started a steady increase above $70,000 and $72,000. BTC is now consolidating and might aim for more gains above $72,800.

Bitcoin started a fresh increase after it settled above the $68,800 support. The price is trading above $70,000 and the 100 hourly simple moving average. There is a bullish trend line forming with support at $68,000 on the hourly chart of the BTC/USD pair (data feed from Kraken). The pair might dip again if it trades below the $72,000 and $70,800 levels. Bitcoin Price Rallies Above $70,000 Bitcoin price managed to form a base above the $67,500 zone. BTC started a fresh increase and was able to surpass the $68,800 resistance zone.

The price even rallied above the $70,000 resistance. Finally, the bears appeared near $74,000. A high was formed at $74,062, and the price recently corrected some gains. There was a move below $73,000, and the price declined toward the 23.6% Fib retracement level of the upward move from the $66,164 swing low to the $74,062 high.

Bitcoin is now trading above $70,000 and the 100 hourly simple moving average. There is also a bullish trend line forming with support at $68,000 on the hourly chart of the BTC/USD pair.

Source: BTCUSD on TradingView.com If the price remains stable above $70,000, it could attempt a fresh increase. Immediate resistance is near the $72,800 level. The first key resistance is near the $73,500 level. A close above the $73,500 resistance might send the price further higher. In the stated case, the price could rise and test the $74,000 resistance. Any more gains might send the price toward the $75,000 level. The next barrier for the bulls could be $76,800 and $77,200.

Downside Correction In BTC? If Bitcoin fails to rise above the $72,800 resistance zone, it could start another decline. Immediate support is near the $72,200 level. The first major support is near the $72,000 level.

The next support is now near the $70,000 zone or the 50% Fib retracement level of the upward move from the $66,164 swing low to the $74,062 high. Any more losses might send the price toward the $68,800 support in the near term. The main support now sits at $68,000, below which BTC might struggle to recover in the near term.

Technical indicators:

Hourly MACD – The MACD is now losing pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for BTC/USD is now above the 50 level.

Major Support Levels – $72,000, followed by $70,000.

Major Resistance Levels – $72,800 and $73,500.

Bitcoin is showing tentative signs of relief after reclaiming the $70,000 level. A move that haskeepingsed selling pressure following weeks of volatile trading. The recovery comes as markets continue to react to macro uncertainty and geopolitical tensions. Which have kept liquidity fragile and investor sentiment cautious. While the push above $70K offers a short-term improvement in momentum, the underlying data suggests that a significant portion of market participants remain under pressure.

According to a recent CryptoQuant report, holders of spot Bitcoin ETFs — which broadly reflect institutional and retail demand through regulated investment vehicles — are currently positioned below their estimated average realized price. Calculated at roughly $79,000, this cost basis leaves the average ETF investor holding a loss despite the recent rebound.

Treat this metric as a reference point, not as a precise measurement of individual investor behavior. ETF flows can obscure internal reallocations between participants, and the estimate cannot perfectly capture every underlying transaction within the funds. Nevertheless, it provides a useful approximation of the aggregate entry level for ETF capital.

Darkfost’s analysis highlights the scale of the recent pressure across spot Bitcoin ETFs. With Bitcoin trading below the $70,000 threshold during much of the correction, these funds recorded the largest drawdown since their all-time high in terms of invested value. In dollar terms, more than $8.9 billion flowed out of the ETF ecosystem as investors reduced exposure during the downturn.

Bitcoin ETF Drawdown from ATH | Source: CryptoQuant The pressure was particularly visible in the largest product in the market. BlackRock’s iShares Bitcoin Trust (IBIT), which once held more than 806,000 BTC at its peak, saw substantial withdrawals throughout the correction. According to the data, over 42,000 BTC exited the fund, reflecting a clear wave of distribution as market sentiment deteriorated and price momentum weakened.

These outflows represented a significant source of selling pressure during the decline, reinforcing the broader weakness across spot markets. When large ETFs experience withdrawals, they often need to redeem Bitcoin to meet redemptions, increasing supply on the market.

However, recent data suggests the situation may be stabilizing. The cumulative drawdown from ETF holdings has improved from roughly −$8.9 billion to around −$7.8 billion from the peak. While still negative, this shift indicates that the pace of outflows is slowing.

A renewed wave of demand from ETF investors would likely help Bitcoin establish a stronger structural base moving forward.

On the 4-hour chart, Bitcoin is showing short-term recovery momentum after pushing above the $70,000 level. Price has managed to reclaim the 50-period moving average (blue) and is now testing the 100-period moving average (green), signaling improving short-term strength after weeks of consolidation and lower highs.

BTC testing critical resistance | Source: BTCUSDT chart on TradingView The recent move above $70K represents an important psychological shift. Throughout late February, the $69,000–$70,000 region acted as a consistent rejection zone where sellers repeatedly capped upside attempts. The latest breakout suggests that buyers are beginning to absorb that supply, at least in the short term.

However, the broader structure remains cautious. Bitcoin is still trading below the 200-period moving average (red), currently positioned near the mid-$70K range. This level continues to represent the key resistance that would need to be reclaimed to confirm a stronger trend reversal.

Volume has modestly increased during the breakout attempt, indicating renewed participation, though not yet at levels typically associated with sustained bullish expansions.

From a technical perspective, holding above $69,000 will be critical for maintaining momentum. If this level flips into support, BTC could attempt a move toward the $73,000–$75,000 region. Conversely, a failure to hold above $69K could return the price to the broader consolidation range around $66,000–$67,000.

Featured image from ChatGPT, chart from TradingView.com 

Ethereum price started a fresh increase above $2,120. ETH is now correcting gains from $2,200 and might decline further below $2,100.

Ethereum started a downside correction from the $2,200 zone. The price is trading above $2,080 and the 100-hourly Simple Moving Average. There is a key bullish trend line forming with support at $2,020 on the hourly chart of ETH/USD (data feed via Kraken). The pair could start a fresh decline if it stays below the $2,180 zone. Ethereum Price Rallies Over 8% Ethereum price started a fresh increase above the $2,050 resistance, like Bitcoin. ETH price rallied above the $2,080 and $2,120 resistance levels.

The bulls even pumped the price above $2,150. A high was formed at $2,200 before there was a downside correction. The price dipped below $2,150 and the 23.6% Fib retracement level of the upward move from the $1,929 swing low to the $2,200 high.

Ethereum price is now trading above $2,080 and the 100-hourly Simple Moving Average. There is also a key bullish trend line forming with support at $2,020 on the hourly chart of ETH/USD.

Source: ETHUSD on TradingView.com If the bulls remain in action above $2,020, the price could attempt another increase. Immediate resistance is seen near the $2,150 level. The first key resistance is near the $2,180 level. The next major resistance is near the $2,200 level. A clear move above the $2,200 resistance might send the price toward the $2,250 resistance. An upside break above the $2,250 region might call for more gains in the coming days. In the stated case, Ether could rise toward the $2,320 resistance zone or even $2,350 in the near term.

Downside Correction In ETH? If Ethereum fails to clear the $2,150 resistance, it could start a fresh decline. Initial support on the downside is near the $2,080 level. The first major support sits near the $2,065 zone or the 50% Fib retracement level of the upward move from the $1,929 swing low to the $2,200 high.

A clear move below the $2,065 support might push the price toward the $2,020 support. Any more losses might send the price toward the $1,980 region. The main support could be $1,920.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is losing momentum in the bullish zone.

Hourly RSI – The RSI for ETH/USD is now above the 50 zone.

Major Support Level – $2,065

Major Resistance Level – $2,180

NEW ORLEANS, March 04, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against CoreWeave, Inc. (NasdaqGS: CRWV), if they purchased or otherwise acquired the Company’s securities between March 28, 2025 and December 15, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

Get Help

CoreWeave investors should visit us at https://claimsfiler.com/cases/nasdaq-crwv/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

CoreWeave and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had overstated its ability to meet customer demand for its service; (ii) the Company materially understated the scope and severity of the risk that its reliance on a single third-party data center supplier created for its ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company’s revenue; and (iv) as a result, CoreWeave's public statements were materially false and misleading at all relevant times.

The case is Masaitis v. CoreWeave, Inc., et al., No. 26-cv-00355.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tyler Technologies, Inc. (TYL) Morgan Stanley Technology, Media & Telecom Conference 2026 March 4, 2026 5:35 PM EST

Company Participants

Brian Miller - Executive VP & CFO

Conference Call Participants

David Chen

Presentation

David Chen

All right. Good afternoon, everyone. I'm David Chen with Morgan Stanley, and I'm very pleased to have Brian Miller here, Chief Financial Officer of Tyler Technologies. Brian, welcome.

Brian Miller
Executive VP & CFO

Thanks. Great to be here.

Question-and-Answer Session

David Chen

All right. So why don't we just kind of get started with, for those of you that are possibly maybe new to the Tyler story. Provide -- just kind of give us the quick sense of the company and the products.

Brian Miller
Executive VP & CFO

Sure. vertical software company focused exclusively on the public sector market. So we provide a wide range of software applications that manage essential mission-critical functions of government. More of -- most of our focus is the local government level. So cities, counties, school districts, local agencies make up about 70% to 75% of our business. Another 20% to 25% is at the state level and less than 5% federal. So not much exposure there.

We have, by far, the largest, broadest product portfolio in the industry, which is a very fragmented space historically as well as the largest customer base. So we've got about 45,000 systems installed across about 15,000 different jurisdictions. Revenues will be about $2.5 billion this year. Market cap is around 15%. And we also have a growing transactions business as well. So we do a lot of things about processing and transaction-based services, especially for state governments, but we're driving that down into our local government base through integration with our software products. So we have a really -- the transactions are about 1/3 of our business today.

Magnachip Semiconductor Corporation (MX) Q4 2025 Earnings Call Transcript

NEW ORLEANS, March 04, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Get Help

Ultragenyx investors should visit us at https://claimsfiler.com/cases/nasdaq-rare/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Ultragenyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.

The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Kyndryl Holdings, Inc. (NYSE: KD) between August 7, 2024 and February 9, 2026, both dates inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

So what: If you purchased Kyndryl securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Kyndryl class action, go to https://rosenlegal.com/submit-form/?case_id=38139 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Kyndryl's financial statements issued during the Class Period were materially misstated; (2) Kyndryl lacked adequate internal controls and at times materially understated issues with its internal controls; (3) as a result, Kyndryl would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025; and (4) as a result, defendants' statements about Kyndryl's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Kyndryl class action, go to https://rosenlegal.com/submit-form/?case_id=38139 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

NEW ORLEANS, March 04, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

Get Help

Corcept investors should visit us at https://claimsfiler.com/cases/nasdaq-cort-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s New Drug Application (“NDA”) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant and that it had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”

On this news, the price of Corcept’s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.

The case is Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Paysafe Limited (NYSE: PSFE) between March 4, 2025 and November 12, 2025, inclusive (the “Class Period”), of the important April 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Paysafe securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Paysafe class action, go to https://rosenlegal.com/submit-form/?case_id=2745 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Paysafe’s ecommerce business had significant exposure to a single high risk client; (2) as a result, Paysafe’s credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk Merchant Category Codes, making its client services difficult to bank; (4) the foregoing issues were likely to have a material negative impact on Paysafe’s revenue growth and overall revenue mix; (5) as a result, Paysafe was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (6) as a result of the foregoing, defendants’ positive statements about Paysafe’s  business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Paysafe class action, go to https://rosenlegal.com/submit-form/?case_id=2745 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW ORLEANS, March 04, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 20, 2026 to file lead plaintiff applications in a securities class action lawsuit against Enphase Energy, Inc. (“Enphase” or the “Company”) (NasdaqGM: ENPH), if they purchased or otherwise acquired the Company’s securities between April 22, 2025 and October 28, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

Get Help

Enphase Energy investors should visit us at https://claimsfiler.com/cases/nasdaq-enph-3/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Enphase Energy and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had overstated its ability to manage its channel inventory; (ii) the Company had overstated its ability to offset the impacts resulting from the termination of the Residential Clean Energy Credit pursuant to Internal Revenue Code Section 25D; and (iii) as a result, the Company overstated its financial and operational prospects.

The case is Tripathi v. Enphase Energy, Inc., No. 26-cv-01380.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW ORLEANS, March 04, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired the Company’s shares between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Get Help

uniQure investors should visit us at https://claimsfiler.com/cases/nasdaq-qure/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

uniQure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

During the Class Period, the Company represented to investors that there was a high likelihood that its leading drug candidate, AMT-130, would receive accelerated approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s planned Biologics License Application (“BLA”) submission in the first quarter of 2026. However, on November 3, 2025, the Company disclosed that “the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission” and as a result, “the timing of the BLA submission for AMT-130 is now unclear.”

On this news, the price of uniQure’s shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025.

The case is Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

3.46K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

LOS ANGELES--(BUSINESS WIRE)---- $EOSE--EOSE Investors Have Opportunity to Join Eos Energy Enterprises, Inc. Fraud Investigation with the Schall Law Firm.

Walmart Inc. (WMT) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

New development adds long-term housing stability for low-income households in South Los Angeles

, /PRNewswire/ -- More South Los Angeles residents will soon have a stable place to call home. Today, Eleos and Health Net marked the start of construction on a new 37-unit affordable housing community at 5637 S. Broadway in South Los Angeles.

Eleos Logo

Top left image, from left to right: Mary Abad, Self Help Venture Fund; Isela Gracian, Office of Supervisor Holly Mitchell; Claudia Monterrosa, Office of Mayor Karen Bass; David Aghaei, Eleos; Dorothy Seleski, Health Net; Ambar Quintanilla, Office of Senator Lola Smallwood Cuevas; Daniel Dayan, Eleos; Joe Iniguez, HTA Construction The project was made possible in part by a $550K investment from Health Net, which helped close the remaining funding gap and advance construction of the 100% affordable development. This is a 100% affordable development — all 37 homes are income-restricted and intended for households with low incomes, rather than a mix of market-rate and affordable units. Community leaders and partners gathered at the site to recognize what this project will deliver for the neighborhood: more housing stability, fewer families priced out of the community, and a clearer path to long-term well-being.

"This project reflects what we're working toward at Eleos: delivering high-quality affordable housing faster, more efficiently, and through meaningful partnerships," said David Aghaei, co-founder and principal of Eleos. "By combining private financing, streamlined policy and philanthropic support, we're showing it's possible to move projects forward without delay and without compromising on quality."

"Congratulations to Eleos Ventures on breaking ground on 37-new homes in our South Los Angeles community," said Los Angeles County Supervisor Holly J. Mitchell. "Eleos and Health Net are showing what's possible with public and private partnerships, together putting residents first. These 37 new homes will strengthen this corridor, improve health outcomes, and help families build a more secure future right here in South L.A."

Faster approvals — without waiting years to start building

The South Broadway development received entitlements and permits in nine months under Mayor Karen Bass' Executive Directive 1; the City's streamlined approval pathway designed to accelerate housing. Unlike many affordable housing developments, the project is privately financed and delivered without public subsidy, applying discipline, speed and cost efficiency to housing residents with the greatest need.

"Too many families are priced out of safe, stable housing — even when they're working full time and doing everything right," said Daniel Dayan, co-founder and principal of Eleos. "This development reflects our commitment to closing that gap and creating homes that strengthen neighborhoods and support long-term stability."

Health Net partnership helps close the gap

The project was supported in part by Health Net, whose grant helped close the remaining funding gap and expand access for residents with the greatest need. Since 2020, Health Net has committed $93 million to housing and homelessness initiatives across California, advancing long‑term stability and improved health outcomes for communities most in need.

"Safe, stable housing changes everything — it improves health, strengthens job stability and protects childhoods," said Dorothy Seleski, Medi-Cal President at Health Net. "We're proud to partner with Eleos to bring affordable homes to South Los Angeles, because when families have a secure place to live, they can focus on getting healthier, working to provide for their families and staying rooted in their neighborhood. Our grant helped close the final funding gap so this community can move from uncertainty to stability, and we'll continue investing in practical solutions that give residents real opportunity for long-term well-being."

Eleos will serve as both the developer and operator of the South Broadway community. Across Los Angeles, Eleos has more than 1,300 housing units completed, under construction, or in its active pipeline. Eleos also works with nonprofit service providers and public agencies to support successful lease-up and long-term stability. Many Eleos properties serve residents who have experienced homelessness, rely on housing vouchers, or fall within the "missing middle" income range that often lacks access to traditional subsidies.

What's next

Construction is now underway, with completion anticipated in summer or fall of 2027.

About Health Net
Founded in California more than 45 years ago, Health Net, LLC ("Health Net"), a company of Centene Corporation, believes that every person deserves a safety net for their health, regardless of age, income, employment status or current state of health. Today, we provide health plans for individuals, families, businesses of every size and people who qualify for Medi-Cal or Medicare. With more than 117,000 of our network providers, Health Net serves more than three million members across the state. We also offer access to substance abuse programs, behavioral health services and managed healthcare products related to prescription drugs. We make these health plans and services available through Health Net and its subsidiaries: Health Net of California, Inc., Health Net Life Insurance Company and Health Net Community Solutions, Inc. These entities are wholly owned subsidiaries of Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to transforming the health of the communities we serve, one person at a time. Health Net and Centene Corporation employ more than 5,700 people in California who work at one of five regional Talent Hub offices. For more information, visit www.HealthNet.com.

About Eleos
Eleos was founded with one goal in mind –– to change the space that people live, work and play in for the better. And all of this was fueled by the housing crisis in Los Angeles, which brought to bear the dire need for affordable solutions for our fellow residents who are seemingly forgotten by the current market-rate housing mix. Eleos regularly works with institutions to apply its expertise and resources to a new model of privately funded affordable housing solutions that drive lasting, permanent change. For additional information about Eleos, visit https://www.eleos.la/.

SOURCE Health Net

645 Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BCS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This writing is for informational purposes only. All opinions expressed herein are not investment recommendations, and are not meant to be relied upon in investment decisions. The author is not acting in an investment advisor capacity and is not a registered investment advisor. The author recommends investors consult a qualified investment advisor before making any trade. This article is not an investment research report, but an opinion written at a point in time. The author's opinions expressed herein address only a small cross-section of data related to an investment in securities mentioned. Any analysis presented is based on incomplete information, and is limited in scope and accuracy. The information and data in this article are obtained from sources believed to be reliable, but their accuracy and completeness are not guaranteed. Any and all opinions, estimates, and conclusions are based on the author's best judgment at the time of publication, and are subject to change without notice. Past performance is no guarantee of future returns.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Oil rose in early Asian trade on prospects of prolonged supply disruptions driven by the Middle East conflict.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Vistagen common stock between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) in the U.S. District Court, Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Vistagen common stock between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”).Investors have until March 16, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder.On December 17, 2025, Vistagen issued a press release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a statistically significant improvement on the primary endpoint of change on the Subjective Units of Distress Scale. In pertinent part, defendants announced the trial did not achieve its primary endpoint and there was no treatment difference between fasedienol and placebo for the secondary endpoints.Following this news, the price of Vistagen’s common stock declined dramatically from a closing market of $4.36 per share on December 16, 2025 to $0.86 per share on December 17, 2025, a decline of more than 80%.
Next Steps:

If you purchased or otherwise acquired Vistagen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.

Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com